Thus, loss of ERF activity by rare genomic loss-of-function mutations or by competition with the TMPRSS2-ERG oncogenic product leads to activation of the androgen receptor pathway and prostate cancer [79]. This evidence concerns the gene ERF and prostate carcinoma.